SAMSUNG PHARMACEUTICAL.CO.,Ltd.
001360 | KO
Overview
Corporate Details
- ISIN(s):
- KR7001360007
- LEI:
- Country:
- South Korea
- Address:
- 경기도 화성시 향남읍 제약공단4길 10 -, 화성시
- Website:
- http://www.sspharm.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-25 00:00 |
Regulatory Filings
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 12.2 KB | ||
| 2025-08-22 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 63.8 KB | ||
| 2025-08-21 00:00 |
Share Issue/Capital Change
유상증자또는주식관련사채등의발행결과(자율공시)
|
Korean | 5.8 KB | ||
| 2025-08-20 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
|
Korean | 134.9 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.1 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 916.3 KB | ||
| 2025-08-08 00:00 |
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
|
Korean | 67.1 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 896.6 KB | ||
| 2025-03-27 00:00 |
AGM Information
정기주주총회결과 (제 71기)
|
Korean | 22.5 KB | ||
| 2025-03-19 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 11.9 KB | ||
| 2025-03-19 00:00 |
Audit Report / Information
사업보고서 (2024.12)
|
Korean | 495.1 KB | ||
| 2025-03-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 9.2 KB | ||
| 2025-03-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 120.2 KB | ||
| 2025-03-12 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 83.1 KB | ||
| 2025-03-12 00:00 |
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
|
Korean | 5.4 KB |
Automate Your Workflow. Get a real-time feed of all SAMSUNG PHARMACEUTICAL.CO.,Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SAMSUNG PHARMACEUTICAL.CO.,Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SAMSUNG PHARMACEUTICAL.CO.,Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Israel
LCTX
Develops topical skin treatments by reformulating drugs with a lipid-based delivery platform.
Sweden
LIPI
Sweden
LIPI
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
United States of America
LPCN
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
United States of America
LQDA
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
United States of America
LSTA
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
United States of America
LGVN
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Switzerland
LONN
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
United States of America
LYEL
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
United States of America
LYRA
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
Norway
LYTIX